<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04319627</url>
  </required_header>
  <id_info>
    <org_study_id>SAVER Trial</org_study_id>
    <nct_id>NCT04319627</nct_id>
  </id_info>
  <brief_title>Statins for Venous Event Reduction in Patients With Venous Thromboembolism</brief_title>
  <acronym>SAVER</acronym>
  <official_title>Statins for Venous Event Reduction in Patients With Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard or usual treatment for patients diagnosed with deep vein thrombosis or pulmonary&#xD;
      embolism is treatment with blood thinners (called anticoagulants).&#xD;
&#xD;
      While treatment of blood clots with blood thinners is effective, some research has shown that&#xD;
      adding a statin (medication used to lower cholesterol) may give extra protection. It is&#xD;
      thought that statins can improve how cells along the walls of the vein control inflammation,&#xD;
      which can prevent new blood clots from forming.&#xD;
&#xD;
      The medication in this study, rosuvastatin, is approved in Canada for use as a&#xD;
      cholesterol-lowering medication. The use of rosuvastatin in this study is considered&#xD;
      investigational. This means that Health Canada has not approved the use of rosuvastatin as a&#xD;
      treatment for blood clots. However, it has been approved for use in this research study.&#xD;
&#xD;
      The purpose of this study is to examine if adding a statin (rosuvastatin) to the usual blood&#xD;
      thinner treatment will decrease the risk of another blood clot forming. The investigators&#xD;
      also hope to discover if taking a statin reduces damage to your veins. To do this, some of&#xD;
      the participants in this study will get rosuvastatin and others will receive a placebo (a&#xD;
      substance that looks like the study rosuvastatin but does not have any active or medicinal&#xD;
      ingredients). The placebo in this study is not intended to have any effect on your blood&#xD;
      clot. A placebo is used to make the results of the study more reliable.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent Major VTE</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Symptomatic recurrent major VTE (proximal DVT or segmental or larger PE) occurring between randomization and the end of follow-up (i.e. completion of the trial) in patients taking generic rosuvastatin as compared with placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post Thrombotic Syndrome</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Post-thrombotic syndrome as measured by the Villalta scale throughout the follow-up period in patients taking generic rosuvastatin as compared with placebo. The Villalta PTS scale has been adopted by the International Society on Thrombosis and Haemostasis (ISTH) as a standard to diagnose and grade the severity of PTS in clinical studies.&#xD;
Points are summed to yield total score: 0-4: No PTS; 5-9: Mild PTS; 10-14: Moderate PTS; 15 or more, or presence of ulcer: Severe PTS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants diagnosed with non-major VTE during follow-up</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Symptomatic non-major VTE (see below) occurring between randomization and the end of follow-up (i.e. completion of the trial) in patients taking generic rosuvastatin as compared with placebo.&#xD;
Non-major VTE:&#xD;
Distal DVT (distal to the trifurcation of the popliteal vein);&#xD;
Isolated sub-segmental PE;&#xD;
Upper extremity DVT;&#xD;
Superficial phlebitis &gt; 5 cm;&#xD;
Superficial phlebitis ≤ 5 cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants diagnosed with an arterial vascular event during follow-up</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Components of composite arterial vascular events (see below) occurring between randomization and the end of follow-up (i.e. completion of the trial) in patients taking generic rosuvastatin as compared with placebo.&#xD;
Components of composite arterial vascular events:&#xD;
Fatal myocardial infarction;&#xD;
Non-fatal myocardial infarction;&#xD;
Hospitalization for unstable angina;&#xD;
Coronary artery revascularization;&#xD;
Sudden cardiac death;&#xD;
Ischemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths during study participation</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>All-cause mortality occurring between randomization and the end of follow-up (i.e. completion of the trial) in patients taking generic rosuvastatin as compared with placebo.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants who have a bleeding event during follow-up</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Bleeding event (major, clinically relevant non-major, minor) occurring between randomization and the end of follow-up (i.e. completion of the trial) in patients taking generic rosuvastatin as compared with placebo.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2700</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Blood Clot</condition>
  <condition>Post Thrombotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the experimental arm will take one rosuvastatin 20 mg tablet by mouth every day for the duration of their participation in the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to the control arm will take one placebo tablet by mouth every day for the duration of their participation in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin Calcium</intervention_name>
    <description>Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Rosuvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Symptomatic objectively confirmed proximal leg DVT (above the trifurcation of the&#xD;
        popliteal vein) and/or PE (segmental or greater) diagnosed in the last 30 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable or unwilling to provide written informed consent;&#xD;
&#xD;
          2. ≤ 18 years of age;&#xD;
&#xD;
          3. Currently prescribed a statin;&#xD;
&#xD;
          4. A known medical history or current diagnosis of any of the following:&#xD;
&#xD;
               -  Diabetes,&#xD;
&#xD;
               -  Abdominal aortic aneurysm,&#xD;
&#xD;
               -  Peripheral arterial disease presumed to be of atherosclerotic origin,&#xD;
&#xD;
               -  Stroke,&#xD;
&#xD;
               -  Transient ischemic attack (TIA),&#xD;
&#xD;
               -  Myocardial infarction (MI),&#xD;
&#xD;
               -  Acute coronary syndromes,&#xD;
&#xD;
               -  Stable/unstable angina,&#xD;
&#xD;
               -  Coronary or other arterial revascularization;&#xD;
&#xD;
          5. Known diagnosis of hypercholesterolemia or dyslipidemia;&#xD;
&#xD;
          6. Contraindication to rosuvastatin:&#xD;
&#xD;
               -  Known hypersensitivity or intolerance to statins,&#xD;
&#xD;
               -  History of muscle disorders or statin-related muscle pain,&#xD;
&#xD;
               -  Known liver disease (active liver disease or unexplained elevations of serum&#xD;
                  transaminases exceeding 3 times the upper limit of normal),&#xD;
&#xD;
               -  Chronic kidney disease (Creatinine clearance &lt; 30ml/min within previous 3&#xD;
                  months),&#xD;
&#xD;
               -  Currently pregnant or breast-feeding,&#xD;
&#xD;
               -  Taking cyclosporine;&#xD;
&#xD;
          7. Unstable medical or psychological condition that would interfere with trial&#xD;
             participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurélien Delluc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lesley Yeung</last_name>
    <phone>+16137378899</phone>
    <phone_ext>71068</phone_ext>
    <email>lyeung@ohri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Penny Phillips</last_name>
    <phone>+16137378899</phone>
    <phone_ext>73440</phone_ext>
    <email>pphillips@ohri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sam Schulman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jim Douketis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Gross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Yeung</last_name>
      <phone>6137378899</phone>
      <phone_ext>71068</phone_ext>
      <email>lyeung@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Aurélien Delluc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Susan Kahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill Univeristy Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Véronique Naessens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Guillaume Roberge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brest University Hospital Centre</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Karine Lacut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fionnuala Ní Áinle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Insubria</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Walter Ageno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam University</name>
      <address>
        <city>Amsterdam</city>
        <state>Holland</state>
        <zip>1098XH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nick Van Es, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ostfold Hopsital</name>
      <address>
        <city>Sarpsborg</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Roaldsnes</last_name>
      <email>Christina.Roaldsnes@so-hf.no</email>
    </contact>
    <investigator>
      <last_name>Waleed Ghanima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rosuvastatin</keyword>
  <keyword>Statin</keyword>
  <keyword>PTS</keyword>
  <keyword>VTE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

